Sign in

You're signed outSign in or to get full access.

Steven Rodgers

About Steven Rodgers

Steven E. Rodgers, age 53, is a Class II independent director of Aveanna Healthcare Holdings Inc. (AVAH), serving on the Board since 2017; his current Class II term runs to the 2026 annual meeting. He is a Managing Director at Morgan Stanley Capital Partners, head of healthcare investing, and a member of the Investment Committee. He holds a BA in Government from Dartmouth College and an MBA from Stanford Graduate School of Business .

Past Roles

OrganizationRoleTenureCommittees/Impact
Morgan Stanley Capital PartnersManaging Director; Partner; Head of Healthcare Investing; Investment Committee member; MSIM Diversity Council member2018–presentLeads healthcare investing; IC oversight
J.H. Whitney Capital PartnersSenior Managing Director; led healthcare investing; Investment Committee memberApr 2013–Mar 2018Led firm’s healthcare investing
PSA Healthcare (predecessor to AVAH)Director2015–2017Board experience in pediatric home care

External Roles

OrganizationRoleStatus
Clarity SoftwareDirectorCurrent
SpendMendDirectorCurrent
U.S. HealthConnectDirectorCurrent
Prescott’sDirectorCurrent
Geisel School of Medicine at DartmouthBoard of AdvisorsCurrent
Magnusson Center for Entrepreneurship (Dartmouth)Board of AdvisorsCurrent
Amisys Synertech; Herbalife; PatientKeeper; Symbion; Ovation Fertility; 3B ScientificDirector (prior)Prior board service

Board Governance

  • Board independence: The Board determined Rodgers is independent under Nasdaq rules .
  • Structure: AVAH is a “controlled company” under Nasdaq; it uses the exemption for the Nominating & Corporate Governance Committee (not all independent), while the Compensation Committee is fully independent .
  • Attendance: In FY2024 the Board met 4 times; Audit and Clinical Quality met quarterly. Each director attended at least 75% of Board and committee meetings. Independent directors meet in executive session regularly .
Governance AttributeDetail
Board classClass II director; term expires at 2026 annual meeting
IndependenceIndependent director (Nasdaq)
CommitteesAudit Committee member; Compensation Committee member
Committee chair rolesNone (Audit Chair: Victor F. Ganzi; Compensation Chair: Devin O’Reilly)
Meeting attendance≥75% in FY2024
Executive sessionsIndependent directors meet in executive session

Fixed Compensation

Component (FY2024)AmountNotes
Annual cash retainer$70,000Standard independent director retainer
Audit Committee member fee$12,500Member retainer
Compensation Committee member fee$7,500Member retainer
Total cash fees (Rodgers)$90,000Disclosed for Rodgers
Annual RSU grant$130,000RSUs vest one year from grant date

Performance Compensation

  • Directors do not receive performance-based awards; independent director equity is time-based RSUs vesting after one year .
MetricFY2024 Director Plan Treatment
Performance metrics (revenue, EBITDA, TSR, ESG)Not applicable to director compensation; RSUs are time-based
Vesting scheduleOne-year cliff vest for director RSUs

Other Directorships & Interlocks

  • Compensation Committee interlocks: None; no members (including Rodgers) were current/former AVAH officers, and no executive served on another entity’s comp committee with reciprocal ties in FY2024 .
  • Controlled company sponsors: Bain Capital and J.H. Whitney beneficially own >50% combined voting power; they nominate a majority of directors under a stockholders agreement (context for board composition). Rodgers is not disclosed as affiliated with these sponsors .

Expertise & Qualifications

  • Private equity healthcare leadership; extensive board experience across healthcare companies .
  • Education: BA Dartmouth; MBA Stanford .
  • Committee experience: Audit and Compensation at AVAH .

Equity Ownership

HolderShares Beneficially Owned% of Shares Outstanding
Steven E. Rodgers265,2370.136% (265,237 / 195,093,866)
  • Ownership calculation uses 195,093,866 shares outstanding as of March 11, 2025 .
  • Stock ownership guidelines: non-employee directors must hold 4× annual retainer; unvested time-based RSUs count; PSUs do not. Compliance status by individual is not disclosed .
  • Hedging/pledging: Prohibited for directors (no hedging, short sales, pledging, or margin purchases) .

Fixed/Variable Mix (FY2024)

TypeAmountStructure
Cash$90,000Retainer + committee member fees
Equity$130,000Annual RSU grant; one-year cliff vest

Risk Indicators & Red Flags

  • Controlled company governance: AVAH relies on the controlled company exemption for the Nominating & Corporate Governance Committee; two members are not independent .
  • Section 16(a) compliance: One Form 4 for Rodgers was inadvertently filed late in 2024 (administrative lapse) .
  • Related party exposure: AVAH purchases Waystar revenue cycle software (~$0.4M FY2024); Waystar is affiliated with Bain Capital (a sponsor). No Rodgers-specific related party transactions disclosed .
  • Trading policies: Robust prohibitions on hedging/pledging mitigate alignment risks .

Director Compensation Policy (Reference)

RoleCash RetainerChair FeeMember FeeEquity
Independent director$70,000~$130,000 RSUs (1-yr vest)
Audit Committee$25,000$12,500
Compensation Committee$15,000$7,500
Nominating & Corporate Governance$12,000$6,000
Clinical Quality$12,000$6,000
Board Chairman$90,000~$150,000 RSUs (1-yr vest)

Compensation Committee Analysis

  • Composition: Devin O’Reilly (Chair), Christopher R. Gordon, Steven E. Rodgers, Robert M. Williams Jr.; all independent under Nasdaq .
  • Consultant: Aon’s Human Capital Solutions engaged in 2023 to inform executive pay and peer group selection .
  • Peer group used (executive comp): 14 healthcare services peers, including Addus, Amedisys, ModivCare, Option Care, Surgery Partners, Pennant, etc. (context for committee’s benchmarking) .
  • Interlocks/insider participation: None in FY2024 .

Governance Assessment

  • Independence and committee roles: Rodgers strengthens board oversight via Audit and Compensation Committee membership, with the Compensation Committee fully independent despite controlled company status .
  • Attendance and engagement: Directors maintained ≥75% attendance; independent directors meet in executive session, indicating board engagement and independent oversight .
  • Alignment: Rodgers’ equity ownership and annual RSU grants plus a prohibition on hedging/pledging support alignment with shareholders, while director RSUs are time-based rather than performance-based .
  • Controls and conflicts: No Rodgers-specific related party transactions disclosed; AVAH’s controlled company structure concentrates nomination influence with sponsors, and there was a single late Form 4 filing for Rodgers in 2024 (administrative) .